HPV vaccine with routine HPV screening for ages 22–26
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman living in Sweden and between 22 and 26 years old
- You have not chosen to opt out of the national cervical/HPV screening program
- You agree to participate in the study and consent
- You are not currently pregnant
- You have not had your uterus removed (no total hysterectomy)
- You do not have a history of severe allergic reaction to the HPV vaccine or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women in the Stockholm area who tested positive for HPV (a virus linked to cervical cancer) to see if and how often cervical cancer develops. It aims to understand the risk better, which could improve screening and prevention.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial aims to develop a vaccine that trains your immune system to fight HPV, the virus that causes cervical cancer. By studying your blood, researchers hope to find better ways to prevent the cancer from coming back.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.
This study looks at how well the HPV vaccine works in women who have already been exposed to the virus through sexual activity. It aims to understand the immune response and potentially improve protection against HPV-related cancers.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.